Address
2223 Avenida de la Playa
La Jolla, CA 92037
United States of America (the)
Phone
619 400 1170
Website
Sector
Healthcare
Industry
Biotechnology
Employees
3
First IPO Date
April 24, 2023
| Name | Title | Pay | Year Born |
| W. Marc Hertz | Co-Founder, Chief Executive Officer, President & Director | 752,482 | 1971 |
| Albert Agro | Co-Founder & Chief Medical Officer | 461,099 | 1965 |
| Vipin Kumar | Co-Founder & Chief Scientific Officer | 469,102 | 1960 |
| Leanne Kelly | Chief Financial Officer & Corporate Secretary | 474,737 | 1977 |
GRI Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutic agents within the United States. Its primary focus lies in addressing inflammatory, fibrotic, and autoimmune disorders. The company's leading drug candidate is GRI-0621, an oral inhibitor targeting type 1 Natural Killer T cells, which is currently undergoing Phase IIa clinical trials. This investigational treatment is being evaluated for severe fibrotic lung conditions, including idiopathic pulmonary fibrosis. Beyond its flagship program, GRI Bio's pipeline also features GRI-0803, a novel oral agonist designed to activate type 2 Natural Killer T cells, currently in preclinical development for autoimmune diseases. Additionally, the company maintains a proprietary library exceeding 500 compounds and includes GRI-0124 and GRI-0729, both aimed at modulating inflammatory immune responses. Founded in 2009 and headquartered in La Jolla, California, GRI Bio, Inc. was previously known as Glycoregimmune, Inc.